Wolverine Asset Management LLC Grows Holdings in Drugs Made In America Acquisition Corp. $DMAA

Wolverine Asset Management LLC raised its position in Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) by 4.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,307,468 shares of the company’s stock after purchasing an additional 58,340 shares during the period. Wolverine Asset Management LLC’s holdings in Drugs Made In America Acquisition were worth $13,564,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sandia Investment Management LP purchased a new position in Drugs Made In America Acquisition in the third quarter valued at $161,000. Quarry LP purchased a new position in Drugs Made In America Acquisition in the third quarter valued at $161,000. Shaolin Capital Management LLC increased its holdings in Drugs Made In America Acquisition by 50.0% in the third quarter. Shaolin Capital Management LLC now owns 150,000 shares of the company’s stock valued at $1,540,000 after buying an additional 50,000 shares in the last quarter. Bulldog Investors LLP increased its holdings in Drugs Made In America Acquisition by 78.5% in the third quarter. Bulldog Investors LLP now owns 130,264 shares of the company’s stock valued at $1,338,000 after buying an additional 57,300 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in Drugs Made In America Acquisition in the third quarter valued at $1,024,000.

Drugs Made In America Acquisition Stock Down 0.1%

DMAA opened at $10.56 on Monday. The company has a fifty day moving average of $10.50 and a two-hundred day moving average of $10.41. Drugs Made In America Acquisition Corp. has a fifty-two week low of $10.07 and a fifty-two week high of $10.57.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank?check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.